Lyell Wealth Management LP Acquires 750 Shares of Stryker Co. (NYSE:SYK)

Lyell Wealth Management LP raised its holdings in Stryker Co. (NYSE:SYK) by 2.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,963 shares of the medical technology company’s stock after purchasing an additional 750 shares during the period. Lyell Wealth Management LP’s holdings in Stryker were worth $9,572,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Farmers & Merchants Trust Co of Chambersburg PA lifted its holdings in shares of Stryker by 203.3% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares during the period. HBC Financial Services PLLC bought a new stake in shares of Stryker during the 4th quarter worth approximately $37,000. Bourgeon Capital Management LLC bought a new stake in shares of Stryker during the 4th quarter worth approximately $37,000. Operose Advisors LLC increased its position in Stryker by 308.6% during the 3rd quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after purchasing an additional 108 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its position in Stryker by 97.1% during the 4th quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock worth $41,000 after purchasing an additional 67 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

NYSE:SYK traded up $1.94 during mid-day trading on Wednesday, hitting $336.85. 1,478,179 shares of the stock traded hands, compared to its average volume of 1,282,265. The business’s 50-day moving average price is $349.39 and its 200 day moving average price is $314.24. The company has a market cap of $128.16 billion, a PE ratio of 40.83, a price-to-earnings-growth ratio of 2.64 and a beta of 0.89. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping analysts’ consensus estimates of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter in the previous year, the company earned $3.00 EPS. The business’s quarterly revenue was up 11.8% compared to the same quarter last year. On average, analysts expect that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a $0.80 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.95%. Stryker’s dividend payout ratio (DPR) is 38.79%.

Insider Activity

In other news, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares in the company, valued at approximately $4,856,522. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the sale, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at $1,317,414. The disclosure for this sale can be found here. In the last 90 days, insiders sold 212,109 shares of company stock valued at $72,845,768. Corporate insiders own 5.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on SYK shares. Citigroup upped their price objective on shares of Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada raised their price target on shares of Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Truist Financial lifted their price objective on shares of Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a report on Wednesday, January 31st. Finally, Wells Fargo & Company boosted their price target on shares of Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a report on Wednesday, January 31st. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $340.67.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.